Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Listen now
Description
Michael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company's emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
More Episodes
Peter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman about his evolving career as a reporter and editor and the impact that Stargardt disease has had on his journey and ambitions. Peter also reflects on recently...
Published 05/24/24
Published 05/24/24
The emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
Published 05/22/24